Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “buy” rating reaffirmed by research analysts at Cowen in a research report issued to clients and investors on Tuesday, The Fly reports.

Separately, BTIG Research initiated coverage on shares of Y-mAbs Therapeutics in a report on Tuesday. They set a “buy” rating and a $35.00 price objective on the stock.

Shares of NASDAQ:YMAB traded down $0.40 during midday trading on Tuesday, hitting $20.75. The stock had a trading volume of 1,250 shares, compared to its average volume of 161,224. Y-mAbs Therapeutics has a 1 year low of $20.00 and a 1 year high of $31.00.

In related news, Director James Healy acquired 500,000 shares of the firm’s stock in a transaction that occurred on Friday, September 21st. The shares were purchased at an average price of $16.00 per share, with a total value of $8,000,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ashu Tyagi acquired 430,174 shares of the firm’s stock in a transaction that occurred on Tuesday, September 25th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $6,882,784.00. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 961,424 shares of company stock worth $15,382,784.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

See Also: What is Considered a Good Return on Equity (ROE)?

The Fly

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.